ImmuPharma plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMPF research report →
Companywww.immupharma.co.uk
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
- CEO
- Timothy Paul McCarthy XIV, FCCA, MBA
- IPO
- 2017
- Employees
- 14
- HQ
- London, GB
Valuation
- Market Cap
- $28.34M
- P/E
- -7.90
- P/S
- 0.00
- P/B
- 67.70
- EV/EBITDA
- -11.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6634.51%
- ROIC
- -971.74%
Performance & Tape
- 52W High
- $0.09
- 52W Low
- $0.08
- 50D MA
- $0.09
- 200D MA
- $0.08
- Beta
- 1.41
- Avg Volume
- 0
Get TickerSpark's AI analysis on IMMPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IMMPF Coverage
We haven't published any research on IMMPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMMPF Report →